
Consider participating in the OUTLAST study for patients who are seeking treatment for meth addiction.
ABOUT OUTLAST
Currently there are no approved medications for the treatment of methamphetamine (meth) use disorder (MUD). OUTLAST is a Phase 2 study evaluating the safety and effectiveness of IXT-m200, an investigational drug, in treatment-seeking individuals who actively use meth.
We are not affiliated with any law enforcement agency. Your participation in the OUTLAST study is confidential and protected.
The purpose of the OUTLAST study is to see if IXT-m200 will decrease relapses, improve the signs and symptoms associated with meth use, and improve the quality of life in treatment-seeking individuals.

WHO CAN JOIN OUTLAST
You may be eligible to participate in the OUTLAST study if you:
-
Are at least 18 years of age
-
Are seeking treatment for meth addiction
-
Have a positive meth drug test during screening
-
Are willing to take saliva drug screens during participation
-
Are willing to share information daily regarding drug use
ABOUT PARTICIPATION IN OUTLAST
Before participating in OUTLAST, you will be screened through a series of steps, to see if you qualify. If you are eligible, you will begin to receive the study drug. The study drug will be administered through an IV line over 30 minutes. You will receive 6 doses of either IXT-m200 or placebo, spaced 4 weeks apart. You will be randomly assigned, like by the flip of a coin, to either IXT-m200 or placebo. The group of patients assigned to IXT-m200 will be compared to the group of patients assigned to placebo to help researchers better understand the effects of IXT-m200. The study team will follow all patients closely throughout study participation. All participants will follow the same visit schedule and will be asked to complete the same study procedures.
As part of the study, you will be asked to record your drug use daily in a smartphone app. You will also use the app to record your saliva drug tests. Remember, your study participation is confidential, and data collected during the study will not be reported to any law enforcement agency. You will also use the app to connect with your recovery coach. Your recovery coach has been where you are today. They are in long-term recovery from their own drug use and know what you are going through. Your recovery coach will be available for a phone and/or video call once per week for the first 3 months and beyond. In addition to the scheduled calls, your recovery coach will be available by text during working hours.

OUTLAST participation is planned for approximately 8 months, and it includes about 10 study visits. The investigational drug, study-related procedures, and doctor visits will be provided at no cost. You will receive some compensation for your participation.
Volunteers are an essential part of developing new medications. We know the decision to participate is a personal one. Thank you for considering OUTLAST.
For more information about OUTLAST or to see if you qualify, text OUTLAST to (844) 400-METH. A member of the study team will contact you within 24 hours. You may also contact the study team nearest you directly to discuss OUTLAST eligibility.
OUTLAST Centers Near You
ARKANSAS
Bentonville, AR
Pillar Clinical Research
Fayz Hudefi, MD, Principal Investigator
Eric Foster, Study Coordinator
(479) 367-2688
ARKANSAS
Little Rock, AR
Woodlands International Research Group
George Konis, MD, Principal Investigator
Polina Thomas, Study Coordinator
(501) 221-8681
CALIFORNIA
San Diego, CA
Artemis Institute for Clinical Research
Eric Chavez, MD, Principal Investigator
Freia Canals Cistero, Study Coordinator
(858) 278-3647 x130
ILLINOIS
Chicago, IL
Pillar Clinical Research
Roueen Rafeyan, MD, Principal Investigator
Dennis Waclawik, Study Coordinator
(224) 534-7332
OHIO
Dayton, OH
Midwest Clinical Research Center
Otto Dueno, MD, Principal Investigator
Marcus McCarty-Towers, Study Coordinator
(937) 424-1050
TEXAS
Desoto, TX
InSite Clinical Research
Raj Shiwach, MD, Principal Investigator
Jill Guge, Study Coordinator
(972) 707-9624
TEXAS
Houston, TX
HD Research
Dominick D'Aunno, MD, Principal Investigator
Tina Allen, Recruitment Coordinator
(281) 369-5765
TEXAS
Richardson, TX
Pillar Clinical Research
Scott Bartley, MD, Principal Investigator
Dana Siler, Study Coordinator
(214) 396-4844
UTAH
Clinton, UT
Alpine Research Organization
M. Scott Roundy, MD, Principal Investigator
Tammie Beickel, Recruitment Coordinator
(801) 803-6417
This study is being sponsored by InterveXion Therapeutics, LLC